149 related articles for article (PubMed ID: 18504514)
1. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.
Chuang YC; Thomas CA; Tyagi S; Yoshimura N; Tyagi P; Chancellor MB
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Oct; 19(10):1353-7. PubMed ID: 18504514
[TBL] [Abstract][Full Text] [Related]
2. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.
Kim Y; Yoshimura N; Masuda H; De Miguel F; Chancellor MB
BJU Int; 2006 Feb; 97(2):400-3. PubMed ID: 16430654
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Kobayashi S; Ikeda K; Miyata K
Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
[TBL] [Abstract][Full Text] [Related]
5. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Kaiho Y; Nishiguchi J; Kwon DD; Chancellor MB; Arai Y; Snyder PB; Yoshimura N
BJU Int; 2008 Mar; 101(5):615-20. PubMed ID: 18070178
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Gillberg PG; Sundquist S; Nilvebrant L
Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
[TBL] [Abstract][Full Text] [Related]
7. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
10. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Moro C; Uchiyama J; Chess-Williams R
Urology; 2011 Dec; 78(6):1442.e9-15. PubMed ID: 22001099
[TBL] [Abstract][Full Text] [Related]
11. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats.
Suzuki M; Ohtake A; Yoshino T; Yuyama H; Hayashi A; Ukai M; Okutsu H; Noguchi Y; Sato S; Sasamata M
Eur J Pharmacol; 2005 Apr; 512(1):61-6. PubMed ID: 15814091
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
Salcedo C; Davalillo S; Cabellos J; Lagunas C; Balsa D; Pérez-Del-Pulgar S; Ballarín M; Fernández A
Br J Pharmacol; 2009 Mar; 156(5):807-17. PubMed ID: 19222482
[TBL] [Abstract][Full Text] [Related]
13. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.
Bharucha AE; Ravi K; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2010 Jul; 299(1):G215-9. PubMed ID: 20395537
[TBL] [Abstract][Full Text] [Related]
14. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
Olshansky B; Ebinger U; Brum J; Egermark M; Viegas A; Rekeda L
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):241-51. PubMed ID: 18832343
[TBL] [Abstract][Full Text] [Related]
16. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats.
Hedlund P; Streng T; Lee T; Andersson KE
J Urol; 2007 Jul; 178(1):326-31. PubMed ID: 17507042
[TBL] [Abstract][Full Text] [Related]
17. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
Mansfield KJ; Chandran JJ; Vaux KJ; Millard RJ; Christopoulos A; Mitchelson FJ; Burcher E
J Pharmacol Exp Ther; 2009 Mar; 328(3):893-9. PubMed ID: 19029429
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological effects of tolterodine on human isolated urinary bladder.
Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
[TBL] [Abstract][Full Text] [Related]
19. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle.
Yono M; Yoshida M; Takahashi W; Inadome A; Ueda S
BJU Int; 2000 Oct; 86(6):719-25. PubMed ID: 11069384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
